The global digital PCR (dPCR) and real-time PCR (qPCR) market is set to expand significantly, with projections indicating growth from USD 10.0 billion in 2024 to USD 14.8 billion by 2029 at a CAGR of 8.1% during the forecast period of 2024 to 2029, driven by factors such as increasing incidences of infectious diseases and genetic disorders, advancements in PCR technologies, and the rising demand for point-of-care diagnostics. However, challenges like lengthy procedures and accuracy issues hinder market growth. Opportunities lie in the integration of PCR technologies in personalized medicine, particularly in drug development through companion diagnostics. Despite competition from alternative technologies like NGS and immunoassays, the market’s ecosystem includes key entities such as major manufacturers (e.g., Danaher Corporation, Thermo Fisher Scientific), research institutes, hospitals, and diagnostic laboratories, positioning North America as the leading regional market.
Browse in-depth TOC on “Digital PCR and Real-Time PCR Market“
907 – Tables
58 – Figures
632 – Pages
Key Players in the Market: Danaher Corporation
Danaher Corporation (US) holds a prominent position in the global digital PCR (dPCR) and real-time PCR (qPCR) markets, owing to its innovative technologies and strategic acquisitions. The company’s portfolio includes high-performance instruments like the QuantStudio and QX200 Droplet Digital PCR Systems, known for their precision and reliability in nucleic acid quantification. By investing heavily in research and development, Danaher continuously introduces state-of-the-art solutions that meet evolving clinical and research laboratory needs. Leveraging a strong global presence and robust distribution network, Danaher ensures broad accessibility to its advanced products, thus maintaining competitiveness and fostering market growth.
Innovative Offerings: F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. (Switzerland) is another major player in the digital PCR (dPCR) and real-time PCR (qPCR) market, renowned for its commitment to innovation. The company’s LightCycler and Cobas platforms set industry standards with their precision, reliability, and user-friendly interfaces. Roche’s digital PCR solutions excel in accurately quantifying nucleic acids, even at low concentrations, while the recently launched LightCycler PRO System underscores Roche’s ongoing advancements in qPCR technology. This system, designed to meet clinical diagnostic and research demands, features enhanced temperature uniformity, improved software algorithms, and a user-friendly interface, positioning Roche competitively in the market.
Strategic Focus: Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc. (US) plays a pivotal role in the Digital PCR (dPCR) and Real-time PCR (qPCR) market, catering to diverse end-users including hospitals, diagnostic laboratories, CROs, CDMOs, and pharmaceutical and biopharmaceutical companies. The company enhances its market presence through strategic initiatives such as product launches and collaborations. Notably, Thermo Fisher’s TaqPath Real-time PCR kits, launched in February 2023 for infectious disease detection in India, highlight its commitment to expanding diagnostic capabilities. Additionally, research partnerships with leading organizations strengthen Thermo Fisher’s research and product development efforts in dPCR and qPCR technologies, reinforcing its competitive edge in the market.
Segmentation Insights: Products and Applications
The market is segmented into reagents and consumables, and instruments, with the former accounting for the largest share and projected to grow at the highest CAGR. This segment benefits from frequent replacement needs and broad application range. In terms of application, clinical applications dominate due to the growing use of qPCR in disease diagnosis and the technological advantages of dPCR and qPCR in precision and absolute quantification of target molecules.
End-User Landscape
End-user segmentation includes hospitals and diagnostic laboratories, academic and research institutes, pharmaceutical and biotechnology companies, CROs and CDMOs, forensic laboratories, and others. Hospitals and diagnostic laboratories lead the market, driven by increased adoption of dPCR and qPCR technologies for efficient disease diagnosis and expanding healthcare infrastructure, particularly in emerging markets.
Regional Insights
Regionally, North America leads the market, followed by Europe and the Asia Pacific. The Asia Pacific region shows the highest growth potential, supported by increasing pharmaceutical R&D activities, demand for novel dPCR and qPCR products, investments by biopharmaceutical companies, and government support for genomics-based research.
Recent Developments of Digital PCR Market
- In May 2024, Qiagen N.V. entered into a cooperative R&D agreement (CRADA) with the US Federal Bureau of Investigation (FBI) to develop a novel test for its QIAcuity digital PCR devices that will boost forensics by improving the quantification of DNA in human samples.
- In March 2024, F. Hoffmann-La Roche Ltd, has received the US Food and Drug approval for its cobas Malaria test for use on the cobas 6800/8800 systems.